Stem Cells in Ophthalmology Update 19: ACT Adds Bascom Palmer as Another Clinical Site for Dry AMD Trials

In an announcement today, Advanced Cell Technology said that Bascom Palmer Eye Institute had received IRB approval to become the third U.S. clinical site for testing ACT’s human embryonic stem cell-derived retinal pigment epithelial cells in the treatment of dry age-related macular degeneration. Bascom Palmer, one of the country’s premier eye institutes, joins UCLA’s Jules Stein Eye Institute and the Wills Eye Institute as the third U.S. site participating in the clinical trials.

The Bascom Palmer trial will be led by acclaimed retinal specialist Dr. Philip Rosenfeld, the father of the use of Avastin in the treatment of the wet (Read more...)

Full Story →